Mission GBM

Home
Glossary of Terms
Brain Cancer News
Brain Cancer Science Talk
Clinical Trials
FAQs
Goals of Care
Investing in Brain Cancer
Julie's Journey
Meet the Team
Archive
About

Brain Cancer Science Talk

Postcards from the Field
Some green shoots of investing progress as MissionGBM welcomes its 300th case
 • 
Scott L. Rakestraw, PhD
Michael Lim, MD – Brain Cancer Science Talk (Episode 7)
Stanford’s Chair of Neurosurgery discusses the promise and challenges associated with immunotherapy for brain tumors
 • 
Scott L. Rakestraw, PhD
30:07
David D. Tran, MD, PhD – Brain Cancer Science Talk (Episode 6)
An Open-Minded and Curious Physician/Scientist Follows the #Data to Innovate a Compelling Protocol for Treating Gliomas
 • 
Scott L. Rakestraw, PhD
58:11
Paul S. Mischel, MD – Brain Cancer Science Talk (Episode 5)
ecDNA, the Importance of Science, #Data and Collaboration, and Upgrading Science in Neuro-Oncology
 • 
Scott L. Rakestraw, PhD
43:30
Samuel Blackman, MD, PhD – Brain Cancer Science Talk (Episode 4)
Physician, Scientist, Entrepreneur…and Humanitarian
 • 
Scott L. Rakestraw, PhD
36:15
John de Groot, MD – Brain Cancer Science Talk (Episode 3)
Immunotherapy, Combination Protocols, Focused Ultrasound and Emerging Technologies for Treating Brain Tumors with Some Thoughts About Improvements to…
 • 
Scott L. Rakestraw, PhD
26:04
Graeme Woodworth, MD – Brain Cancer Science Talk (Episode 2)
Neurosurgical Techniques to Treat Brain Cancers and Enhance Transport of Therapeutic Agents Across the Blood Brain Barrier
 • 
Scott L. Rakestraw, PhD
34:34
Michael L. Dougan, MD, PhD – Brain Cancer Science Talk (Episode 1)
Understanding and Managing Immune-Related Adverse Events in Immuno-Oncology Protocols
 • 
Scott L. Rakestraw, PhD
32:14
Coming Soon: Brain Cancer Science Talk Series
Leading brain cancer scientists and physicians discuss their state-of-the-art research with MissionGBM
 • 
Scott L. Rakestraw, PhD
CAR-Ts and GBM: A Long Way Yet to Go
Are you ready for a N-valent CAR-T (N>4) with concomitant checkpoint inhibition…and the (S)AEs that come with it…to be available in perhaps 10 years?
 • 
Scott L. Rakestraw, PhD
Immuno-Oncology: A Question of Balance
A SARS-CoV-2 infection precipitates a cascading series of immunological adverse events
 • 
Scott L. Rakestraw, PhD
Results That Matter
Team Julie delivers a remarkable outcome based on leading edge clinical science
 • 
Scott L. Rakestraw, PhD
© 2025 Scott L. Rakestraw, PhD
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture